AC
SONN

Armistice Capital’s Sonnet BioTherapeutics SONN Stock Holding History

Armistice Capital’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,000
Closed -$255K – 318
2024
Q2 		$255K Buy
+34,000
New +$459K ﹤0.01% 196

Other funds holding SONN

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $381M AUM 19.19% 1-Year Est. Return

Armistice Capital's SONN Position: Q3 2024 in Review

Armistice Capital sold out of Sonnet BioTherapeutics (SONN) in Q3 2024, closing a stake of 34,000 shares — an estimated $255K sold.

Armistice Capital first reported a position in SONN in Q2 2024 and held it in 1 quarter. The position peaked at $255K in Q2 2024. 2 funds tracked by Wall St. Rank hold SONN as of Q3 2024.

  • Armistice Capital reported no remaining Sonnet BioTherapeutics position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 34,000 Sonnet BioTherapeutics shares in Q3 2024, an estimated $255K.
  • Armistice Capital first reported a position in Sonnet BioTherapeutics in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's Sonnet BioTherapeutics position peaked at $255K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.